Blueprint Medicines Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$1.1B

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Blueprint Medicines's estimated annual revenue is currently $107.2M per year.(i)
  • Blueprint Medicines received $345.0M in venture funding in March 2019.
  • Blueprint Medicines's estimated revenue per employee is $149,679
  • Blueprint Medicines's total funding is $1.1B.
  • Blueprint Medicines's current valuation is $4.6B. (January 2022)

Employee Data

  • Blueprint Medicines has 716 Employees.(i)
  • Blueprint Medicines grew their employee count by 19% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$109.4M70614%N/AN/A
#9
$6.2M40233%N/AN/A
#10
$1.9M12-20%N/AN/A

Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients lives. We don't think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$1.1B

Total Funding

716

Number of Employees

$107.2M

Revenue (est)

19%

Employee Growth %

$4.6B

Valuation

N/A

Accelerator

Blueprint Medicines News

2022-04-17 - The Access to Comprehensive Genomic Profiling Coalition ...

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders.

2022-04-13 - After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer -

After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer · The data were shared at the American...

2022-03-22 - Blueprint Medicines' AYVAKYT® (avapritinib) Receives ...

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders.

2021-10-28 - Blueprint Medicines Reports Third Quarter 2021 Financial Results - Form 8-K

Blueprint Medicines Reports Third Quarter 2021 Financial Results -- Strong AYVAKIT launch in advanced SM with $17.3 million in net product revenues in the first full quarter following U.S. approval -- -- Raising guidance for 2021 total revenue to $170-$180 million, based on portfolio progress ...

2021-09-03 - Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 3, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on September 1, 2021, the Compensation Committee of Bluepr ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$221.8M72038%N/A
#2
$53.7M752-50%$484M
#3
$97.7M75247%$1.1B
#4
$156.3M75436%$90M
#5
$215.2M76121%N/A

Blueprint Medicines Funding

DateAmountRoundLead InvestorsReference
2014-01-08$25.0MBNextech Invest LtdArticle
2014-11-13$50.0MCPartner Fund ManagementArticle
2016-12-07$143.8MUndisclosedGoldman, Sachs & CoArticle
2016-12-14$134.5MUndisclosedGoldman, Sachs & Co.Article
2017-03-30$230.0MUndisclosedGoldman, Sachs & CoArticle
2017-04-05$215.6MUndisclosedGoldman, Sachs & CoArticle
2017-12-12$316.2MUndisclosedGoldman Sachs & Co. LLCArticle
2017-12-14$345.0MUndisclosedGoldman Sachs & Co. LLCArticle
2019-03-28$345.0MUndisclosedGoldman Sachs & Co. LLCArticle